Virbac Unveils Canine Cephalexin Tablet

Posted: Sept. 5, 2012, 8:05 p.m. EDT



Published:

Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs, the company reported Tuesday.

The FDA-approved drug, called Rilexine, is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Previously, veterinarians often relied on the generic human form of cephalexin to treat dogs, but Rilexine is the first drug of its kind approved by the U.S. Food and Drug administration for the veterinary market, Virbac reported. The new drug should overcome some of the drawbacks of prescribing human cephalexin off-label, including a bitter, metallic taste and strong odor, a lack of veterinary-specific guidelines and the inability to tailor doses, Virbac noted.

Pyoderma is one of the most common diseases seen in dogs, and secondary superficial bacterial pyoderma is the most common form of pyoderma, according to Virbac.

Rilexine is available in 150 mg, 300 mg and 600 mg scored doses. The drug should not be prescribed to dogs that have a known allergy to cephalexin or the B-lactam group of antibiotics.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

AVMA Economic Summit Set for October 24 to 25

The annual event will be held in Schaumburg, Ill.

African Boerboel Delivers Large Litter at Auburn University College of Veterinary Medicine.

Nineteen babies in total.

Study: Early Neutering Poses Health Risks for German Shepherds

The study from UC Davis researchers found that neutering or spaying triples the risk of one or more joint disorders in these dogs.

Add your comment:
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module